{
    "nct_id": "NCT04870515",
    "official_title": "TRIPLE-A PILOT: Actively Intercepting ADT-Induced Metabolic Aberrations in Newly Diagnosed Prostate Cancer",
    "inclusion_criteria": "* Age >= 40 years\n* Histologically confirmed adenocarcinoma of the prostate, (D'Amico risk category intermediate or high risk, localized or locoregional)\n* Primary treatment is RT + ADT [Zoladex, Lupron, Degarelix, and other luteinizing hormone-releasing hormone (luteinizing hormone releasing hormone [LHRH])-directed therapies] with standard RT dose and fractionation (anti-androgen monotherapy will not be allowed\n* Physically able to undertake an exercise program\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 40 Years",
    "exclusion_criteria": "* Advanced, metastatic disease\n* Planning to join a commercial/structured diet change or fitness program\n* Have significant pre-existing T2D (poor glycemic control while on medication, defined as hemoglobin A1c of >= 10 within the prior 12 months) or significant pre-existing cardiovascular disease (CVD) (myocardial infarction or stroke within prior six months)\n* Physician confirmed cognitive impairment or alcohol/narcotic abuse",
    "miscellaneous_criteria": ""
}